Showing results (131-140 of 336) with videos related to

Sort By:
Pageof 34
Cancers|February 11, 2023
Blastoid B-Cell Neoplasms: Diagnostic Challenges and SolutionsLianqun Qiu, Sa A Wang, Guilin Tang, et al.
Frontiers in Allergy|November 4, 2024
Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptomsMatthew J Hamilton, Loren W Greene, Lauren M Madigan, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 11, 2014
MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapyMin Zhou, Jing Wang, Jian Ouyang, et al.
Medicine|October 15, 2016
Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case reportLanshan Huang, Sa A Wang, Sergej Konoplev, et al.
European Journal of Haematology|September 20, 2017
Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotypeWei Wang, Mark J Routbort, Zhenya Tang, et al.
Histopathology|February 22, 2020
Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasmsHong Fang, Guilin Tang, Sanam Loghavi, et al.
European Journal of Haematology|March 27, 2015
Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutationJie Peng, Zhuang Zuo, Bin Fu, et al.
Leukemia & Lymphoma|July 24, 2020
Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemiaZhining Chen, Shimin Hu, Sa A Wang, et al.
Ejhaem|April 23, 2025
Concurrent Bone Marrow Acute Undifferentiated Leukemia and Mediastinal T-Lymphoblastic Lymphoma With Identical SET::NUP214 Fusion and PHF6 and EZH2 MutationsQing Wei, Fatima Z Jelloul, Sa A Wang, et al.
Leukemia & Lymphoma|August 22, 2015
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment responseJie Peng, Robert P Hasserjian, Guilin Tang, et al.
Pageof 34